FOA
REGN icon

Five Oceans Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Five Oceans Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-205
Closed -$216K – 198
2024
Q3 		$216K Sell
205
-25
-11% -$27.8K 0.1% 172
2024
Q2 		$242K Sell
230
-51
-18% -$49.4K 0.13% 137
2024
Q1 		$270K Hold
281
– – 0.14% 135
2023
Q4 		$247K Sell
281
-7
-2% -$5.76K 0.14% 131
2023
Q3 		$237K Buy
288
+2
+0.7% +$1.57K 0.15% 119
2023
Q2 		$206K Sell
286
-6
-2% -$4.63K 0.13% 143
2023
Q1 		$240K Buy
+292
New +$220K 0.16% 124

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Five Oceans Advisors's REGN Position: Q4 2024 in Review

Five Oceans Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 205 shares — an estimated $216K sold.

Five Oceans Advisors first reported a position in REGN in Q1 2023 and held it in 7 quarters. The position peaked at $270K in Q1 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Five Oceans Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Five Oceans Advisors sold 205 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $216K.
  • Five Oceans Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Five Oceans Advisors's Regeneron Pharmaceuticals position peaked at $270K in Q1 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Five Oceans Advisors's 13F filing for Q4 2024, filed 24 Jan 2025.